Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome

Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome

IntroductionMonoclonal antibodies (mAb) targeting plasma cells are malignant gammopathy designed and approved therapies. In recent years, these antibodies have also been increasingly introduced for non-malignant conditions such as autoimmune-mediated diseases. The Anti-Phospholipid Syndrome (APS) is...

Full description

Bibliographic Details
Main Authors: Daniel E. Pleguezuelo, Raquel Díaz-Simón, Oscar Cabrera-Marante, Antonio Lalueza, Estela Paz-Artal, Carlos Lumbreras, Antonio Serrano Hernández
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Immunology
Subjects:
anti-phospholipid
refractory
treatment
daratumumab
anti-CD38
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.667515/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.667515/full

Similar Items